Skip to main content
Erschienen in: Trials 1/2023

Open Access 01.12.2023 | Correction

Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients

verfasst von: Wei Bai, Fan Yang, Huji Xu, Wei Wei, Hongbin Li, Liyun Zhang, Yi Zhao, Xiaofei Shi, Yan Zhang, Xiaofeng Zeng, Xiaomei Leng

Erschienen in: Trials | Ausgabe 1/2023

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Wei Bai and Fan Yang contributed equally to this study.
The original article can be found online at https://​doi.​org/​10.​1186/​s13063-023-07087-5.
Correction: BMC Trials 24, 112 (2023)
https://doi.org/10.1186/s13063-023-07087-5
Following publication of the original article [1], we have been notified that affiliations 1 to 4 are actually different titles within the same department and should be gathered under just one affiliation.
Additionally, the following sentence was added in the Funding section: This study was supported by the National High Level Hospital Clinical Research Funding (2022-PUMCH-A-227).
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction: A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients
verfasst von
Wei Bai
Fan Yang
Huji Xu
Wei Wei
Hongbin Li
Liyun Zhang
Yi Zhao
Xiaofei Shi
Yan Zhang
Xiaofeng Zeng
Xiaomei Leng
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
Trials / Ausgabe 1/2023
Elektronische ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-023-07546-z

Weitere Artikel der Ausgabe 1/2023

Trials 1/2023 Zur Ausgabe